Delayed or failed engraftment remains a concern after cord blood transplantation (CBT) even when using double-unit grafts. Therefore, we analyzed the association between BM assessment performed approximately 21 days after transplantation, and the speed and success of sustained donor-derived neutrophil engraftment in 56 myeloablative double-unit CBT (DCBT) recipients. Overall, the cumulative incidence of sustained neutrophil engraftment was 95% (95% confidence intervals (CI): 89 --100). Of the percentage of myeloid precursors, the BM cellularity and the total donor chimerism the total donor chimerism percentage had the most critical association with the speed and success of engraftment. DCBT recipients who were 100% donor achieved a 98% engraftment rate at a median of 22 days. This compared with 100% engraftment in patients who were 90 --99% donor, but at a delayed median of 29 days and only 68% engraftment in patients o90% donor at a median of 37 days (P ¼ 0.001). Multivariate analysis was performed in the subgroup of patients who had not engrafted at the time the BM analysis was performed, the subgroup of most clinical concern. This confirmed donor chimerism was predictive of subsequent neutrophil recovery (P ¼ 0.004). These findings demonstrate the importance of the day 21 BM chimerism determinations after DCBT.
INTRODUCTION
Cord blood (CB) is an important alternative hematopoietic stem cell source. However, although CB may have advantages, delayed or failed engraftment remains a concern even with double-unit grafts. Total nucleated cell, CD34 þ cell and colony-forming unit doses as well as HLA match have been shown to influence neutrophil engraftment in single-unit CB transplantation. 1 --5 In double-unit CB transplantation (DCBT), the infused CD34 þ cell and colony-forming unit dose of the engrafting unit dictate the speed and success of neutrophil engraftment, although engraftment is also influenced by the total nucleated cell dose (both units combined). 6 However, in individual patients, it is usually not possible to predict from the graft characteristics on transplantation day whether a patient's engraftment will be successful. We, therefore, routinely perform BM analyses approximately 21 days after DCBT to assess engraftment, and now report the association between day 21 BM aspirate and biopsy composition, and donor chimerism and the speed and success of sustained donor-derived neutrophil engraftment in 56 myeloablative DCBT recipients.
MATERIALS AND METHODS
All cord blood transplant (CBT) recipients transplanted during the study period received double-unit grafts. 7, 8 All consecutive eligible patients were included in this analysis. Eligible patients had hematological malignancies consisting of acute leukemia in morphological remission, myelodysplasia with o5% blasts and Non-Hodgkins lymphoma without morphological BM involvement at pre-transplant work-up. In addition, they were recipients of first allograft using myeloablative conditioning and underwent BM analysis approximately 21 days after DCBT. Units were selected according to total nucleated cell dose X1.5 Â 10 7 /kg per unit, 4 --6/6 HLA-A, -B Ag, -DRB1 allele match and CB bank. 6, 9 All patients received fludarabine-based myeloablative conditioning except three in whom clofarabine was substituted (as summarized in Table 1 ), a calcineurin inhibitor with mycophenolate mofetil as immunosuppression, G-CSF, and no antithymocyte globulin as previously described. 6, 9 Patients were transplanted between October 2005 and October 2009. Median follow-up of survivors was 23 months (range 7 --57). Informed consent to transplantation and analysis of transplant outcome was obtained.
BM aspirates and biopsies were obtained from the iliac crests at a median of 21 days (range 19 --27) after transplantation as clinically appropriate. Wright-Giemsa-stained aspirate smears had a 200-cell differential (unless acellular). Biopsies were fixed in buffered formalin followed by decalcification, paraffin embedding and hematoxylin-eosin staining, and analyzed for percentage cellularity (0, 1, 5 and 10% in 10% increments) and the presence of megakaryocytes. Donor chimerism was determined serially on BM and blood using semiquantitative PCR assays of informative polymorphic STRs. 7, 10, 11 BM analyses were performed by hematopathologists blinded to engraftment outcome.
Standard engraftment definitions were used. 9 Sustained engraftment was defined as sustained donor-derived neutrophil recovery (that is, initial engraftment and no secondary graft failure) with achievement of chimerism X90% (both units combined). Neutrophil and platelet engraftment were estimated using cumulative incidence with 95% CI. Death before engraftment was the competing risk. The dominant unit was the only one detected or contributed 450% total chimerism in serial testing. For the purposes of analysis, the percentages of myeloid precursors in the aspirate were divided into 0%, 1 --50% and 450%, and 0, 1 and X5% for biopsy cellularity. The log-rank statistic was used to estimate statistical significance in univariate analyses, and Cox regression was used to estimate the hazard ratio and significance of differences between groups in the multivariate analysis.
RESULTS
Patient and graft demographics are summarized in Table 1 . The 56 patients (median age 29 years) were transplanted predominantly for acute leukemia or lymphoma. The median infused total nucleated cell doses were 2.7 Â 10 7 /kg for the larger unit and 1.9 Â 10 7 /kg for the smaller unit, with a donor-recipient HLA-match that was predominantly 5/6 or 4/6.
Two patients had primary graft failure and one had early secondary graft failure (initial engraftment on day 16 and secondary graft failure onset 24 days after transplant). Two were recipients of high-dose myeloablative conditioning and one was a recipient of intermediate intensity but myeloablative conditioning. Thus, the cumulative incidence of sustained neutrophil engraftment was 95% (95% CI: 89 --100), and neutrophil recovery occurred at a median of 24 days (range 13 --40) after transplantation. The cumulative incidence of day 180 platelet engraftment X50 Â 10 9 /L was 79% (95% CI: 68 --90).
Association between percentage of myeloid precursors in the BM aspirate and neutrophil engraftment Day 21 aspirates were frequently hypocellular with 18 (32%) being acellular. Although the percentages of blasts or lymphoid cells were not associated with engraftment, an aspirate myeloid precursor percentage (granulocytes and granulocyte precursors excluding blasts, median 40%, range 0--87) of 450% was associated with an improved neutrophil engraftment on univariate analysis (P ¼ 0.018, Figure 1a ). Although high rates of sustained engraftment were also seen in patients with lower percentages of myeloid precursors, the rate of neutrophil recovery was slower. In the 36 patients without neutrophil recovery by the day the BM biopsy was performed, a subgroup of particular clinical concern, the aspirate did not predict subsequent engraftment (P ¼ 0.187, Figure 1b ).
Association between biopsy cellularity and neutrophil engraftment Biopsies were also often markedly hypocellular (median cellularity 5%, range 0 --80), and a morphological appearance suggestive of AML was reported in four patients. This correlated with prominent myeloid activity in the aspirates (40 --69%), but the immature cells were of donor origin. A BM cellularity of X5% was associated with enhanced neutrophil engraftment on univariate analysis (P ¼ 0.008, Figure 2a ). BM cellularity was also predictive of subsequent neutrophil engraftment in those who had not yet been engrafted when the BM analysis was performed (P ¼ 0.038, Figure 2b ). Figure 1 . Cumulative incidence of sustained donor neutrophil engraftment after myeloablative DCBT according to the percentage myeloid precursors on the day 21 BM aspirate in all patients (a) and in patients who had not been engrafted at the time the BM analysis was performed (b). Although there was a significant association between the BM aspirate and neutrophil engraftment when all patients were analyzed (a), the percentage of myeloid precursors was not predictive of subsequent engraftment (b). Association between total donor chimerism and neutrophil engraftment Donor hematopoiesis was detected in all patients on day 21 (one unit in 49 and two in 7 patients). In the 53 patients with sustained engraftment, the median total donor chimerism (unit#1 þ unit#2) was 100% (range 65 --100). The three patients with graft failure had a dominant unit (27, 80 and 100% donor), but donor hematopoiesis did not result in sustained recovery. The pattern of chimerism was not affected by the conditioning regimen (data not shown).
No differences in neutrophil recovery were detected in patients engrafting with 1 vs 2 units (data not shown). However, the 41 patients who were 100% total donor had a significant advantage with a 98% engraftment incidence at a median of 22 days. This compared with 100% engraftment but at a delayed median of 29 days in those who were 90 --99% donor, and only 68% if o90% donor at a median of 37 days (P ¼ 0.001, Figure 3a) . Furthermore, total donor chimerism was the most critical predictor of subsequent neutrophil engraftment in the 36 patients who had not engrafted at the time the BM analysis was performed (P ¼ 0.004, Figure 3b) .
The achievement of 100% donor on day 21 also predicted platelet recovery by day 180. Eighty-three percent (95% CI: 71 --95) of patients who were 100% donor had platelet recovery as compared with 67% (95% CI: 42 --91) if o100% donor (relative risk (RR) 0.43, P ¼ 0.028).
Multivariate analysis
To confirm the importance of total donor chimerism, a multivariate analysis to test the ability of the three BM variables to predict subsequent neutrophil engraftment was done in the 36 patients who had not engrafted by the time of the BM analysis was performed (usually day 21). We included the infused viable CD34 þ cell dose/kg of the unit that was dominant in engraftment, as we have previously identified this as a critical determinant of the speed and success of engraftment in this patient population. 6, 12 We confirmed that a total donor chimerism o90% was an independent predictor of impaired engraftment (P ¼ 0.002, Table 2 ). A BM biopsy showing 0% cellularity was also significant whereas the percentage of myeloid precursors in the aspirate was not. 
Sustained neutrophil engraftment
Sustained neutrophil engraftment Figure 3 . Cumulative incidence of sustained donor neutrophil engraftment after myeloablative DCBT according to the total donor chimerism on the day 21 BM biopsy in all patients (a) and in patients not engrafted at the time the BM analysis was performed (b). Total donor chimerism had a highly significant association with engraftment (a) and was the most critical factor predicting subsequent engraftment (b).
DISCUSSION
The association between BM morphological and chimerism analyses and the success of CB engraftment has not been systematically addressed, and existing studies have been restricted to single-unit CBT. 13, 14 As reported following single-unit CBT, 13, 15 we found BM aspirates and biopsies performed early after transplantation were often profoundly hypocellular, and some patients had a predominance of very immature cells on the day 21 BM that were of donor origin. This latter finding reinforces the need for careful correlation of BM morphology with cytogenetic and molecular analyses after DCBT in leukemic patients. More importantly, we found that aspirate myeloid precursors o50% and biopsy cellularity o5% are associated with impaired engraftment after DCBT. However, although an aspirate without myeloid activity or a near empty biopsy was associated with delayed engraftment, it did not necessarily portend graft failure. Notably, in patients who had not been engrafted by the time the BM analysis was performed, the aspirate did not predict subsequent engraftment, and 93% of patients without myeloid precursors on the aspirate were subsequently engrafted. Similarly, nearly all patients with at least 1% cellularity on the biopsy were subsequently engrafted.
Most critical, however, was the chimerism analysis. In the transplantation of hematopoietic stem cells from adult donors, the focus in chimerism testing has been on the potential ability of lineage-specific analysis of the peripheral blood to predict graft rejection and GVHD after non-myeloablative and reduced intensity conditioning. 16, 17 Traditionally, chimerism has not been recommended in recipients of myeloablative conditioning when transplanting unmodified grafts from adult donors, 16 and two recent studies have suggested that chimerism testing of the BM is of limited usefulness in the myeloablative setting. 18, 19 In DCBT, the focus in chimerism analysis has been on the pattern of unit dominance (reviewed in ref. 20) without detailed analysis of the determinants of engraftment success. In our study, total donor chimerism was significantly associated with the speed and success of neutrophil recovery, and was the most predictive of subsequent engraftment in those patients who had not been engrafted by the time the BM analysis was performed. The lack of host, and not whether the patient engrafted with 1 vs 2 units, was critical. This may suggest that the ability of the graft to eradicate host hematopoiesis determines allogeneic engraftment. Total donor chimerism also predicted subsequent platelet recovery.
Our findings concerning chimerism are in contrast to those in myeloablative transplantation of adult stem cell sources but consistent with those of Moscardo et al.
14 after single-unit CBT, and have not previously been reported in double-unit CBT. We conclude that patients transplanted in remission with early neutrophil recovery by day 21 may only need chimerism performed to confirm donor-mediated hematopoiesis. This could potentially be done on the peripheral blood. By contrast, those without neutrophil recovery should have aspirate, biopsy and expedited chimerism analyses. Patients without subsequent count recovery or who have o90% total donor chimerism should have repeat BM analyses on day 28, and a backup graft should be secured in case engraftment does not ensue. Future studies should investigate the mechanism underlying the engraftment advantage of complete donor chimerism.
